title: [Which action mechanisms are secured in the treatment of radiogenic side effects by hyperbaric oxygenation? Comment on the article by A. Hartmann, M. Almeling, U. M. Carl, Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects, Strahlenther Onkol l996, 172, 641-8 (No. 12)].
authors.forename: C
authors.initials: C
authors.lastname: Thilmann
authors.forename: I A
authors.initials: IA
authors.lastname: Adamietz
authors.forename: H D
authors.initials: HD
authors.lastname: Böttcher
mesh_terms: D043925:Angiogenesis Inducing Agents; D000818:Animals; D002478:Cells, Cultured; D006801:Humans; D006931:Hyperbaric Oxygenation; D018919:Neovascularization, Physiologic; D010025:Osteoradionecrosis / Q000628:therapy; D011832:Radiation Injuries / Q000628:therapy*; D011833:Radiation Injuries, Experimental / Q000628:therapy; D051381:Rats
chemical_list: D043925:Angiogenesis Inducing Agents
vernacular_title: Welche Wirkmechanismen sind gesichert bei der Behandlung radiogener Nebenwirkungen durch hyperbare Oxygenierung? Zu dem Beitrag von A. Hartmann, M. Almeling, U. M. Carl: Hyperbare Oxygenierung (HBO) zur Behandlung radiogener Nebenwirkungen: Strahlenther Onkol 1996;172:641-8 (Nr. 12).